Amino acid catabolism in Alzheimer's disease brain: friend or foe?

JWD Griffin, PC Bradshaw - Oxidative medicine and cellular …, 2017 - Wiley Online Library
There is a dire need to discover new targets for Alzheimer's disease (AD) drug development.
Decreased neuronal glucose metabolism that occurs in AD brain could play a central role in …

β-Carboline as a privileged scaffold for multitarget strategies in Alzheimer's disease therapy

A Beato, A Gori, B Boucherle… - Journal of Medicinal …, 2021 - ACS Publications
The natural β-carboline alkaloids display similarities with neurotransmitters that can be
favorably exploited to design bioactive and bioavailable drugs for Alzheimer's disease (AD) …

Serotonergic system, cognition, and BPSD in Alzheimer's disease

S Chakraborty, JC Lennon, SA Malkaram, Y Zeng… - Neuroscience …, 2019 - Elsevier
Abstract Behavioral and Psychological Symptoms of Dementia (BPSD), present in almost
90% of patients with Alzheimer's Disease (AD), cause extensive impairment leading to …

Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo …

D Wilkinson, K Windfeld… - The Lancet …, 2014 - thelancet.com
Background In human beings, 5-HT 6 receptors are almost exclusively expressed in the
brain, particularly in areas relevant for cognition, such as the hippocampus and frontal …

Serotonin 5-HT6 Receptor Antagonists for the Treatment of Cognitive Deficiency in Alzheimer's Disease

B Benhamú, M Martín-Fontecha… - Journal of medicinal …, 2014 - ACS Publications
Alzheimer's disease (AD) is one of the most frequent causes of death and disability
worldwide and has a significant clinical and socioeconomic impact. In the search for novel …

Drug repositioning with adaptive graph convolutional networks

X Sun, X Jia, Z Lu, J Tang, M Li - Bioinformatics, 2024 - academic.oup.com
Motivation Drug repositioning is an effective strategy to identify new indications for existing
drugs, providing the quickest possible transition from bench to bedside. With the rapid …

Microglial dysfunction connects depression and Alzheimer's disease

LE Santos, D Beckman, ST Ferreira - Brain, behavior, and immunity, 2016 - Elsevier
Alzheimer's disease (AD) and major depressive disorder (MDD) are highly prevalent
neuropsychiatric conditions with intriguing epidemiological overlaps. Depressed patients …

Cross talk between brain innate immunity and serotonin signaling underlies depressive-like behavior induced by Alzheimer's amyloid-β oligomers in mice

JH Ledo, EP Azevedo, D Beckman… - Journal of …, 2016 - Soc Neuroscience
Considerable clinical and epidemiological evidence links Alzheimer's disease (AD) and
depression. However, the molecular mechanisms underlying this connection are largely …

A comprehensive review of multi-target directed ligands in the treatment of Alzheimer's disease

C Pathak, UD Kabra - Bioorganic Chemistry, 2024 - Elsevier
Alzheimer's disease (AD) is the most common form of dementia affecting specifically older
population. AD is an irreversible neurodegenerative CNS disorder associated with complex …

[HTML][HTML] Constitutive and acquired serotonin deficiency alters memory and hippocampal synaptic plasticity

SP Fernandez, A Muzerelle… - …, 2017 - nature.com
Abstract Serotonin (5-HT) deficiency occurs in a number of brain disorders that affect
cognitive function. However, a direct causal relationship between 5-HT hypo-transmission …